ASCO’s 2021 Advance of the Year highlights how progress in the treatment of gastrointestinal (GI) cancers is driven by molecular testing of tumors.
The 2020 Advance of the Year in ASCO’s Clinical Cancer Advances report is the refinement of surgical treatment of cancer.
In 2019, ASCO recognizes the progress in treating rare cancers as the Advance of the Year. Impressive progress has been made in bringing new treatment advances to cancers that are rare and difficult to treat. This year’s Clinical Cancer Advances report describes emerging treatments for thyroid cancer, uterine cancer, desmoid tumor, neuroendocrine tumor, and tenosynovial giant cell tumor.
The 2018 Clinical Cancer Advances report of the American Society of Clinical Oncology has crowned an adoptive cell immunotherapy as its Advance of the Year. What is this innovative cancer treatment? What are the risks and benefits?
The 2017 Clinical Cancer Advances report of the American Society of Clinical Oncology has announced that the Advance of the Year is Immunotherapy 2.0. Why 2.0? Because the role of immunotherapy in cancer care is expanding, and oncologists are learning how to use it more effectively.
Immunotherapy made exciting strides in 2015. Because of its potential, ASCO named it the 2016 Clinical Cancer Advance of the Year.
Recognizing the dramatic advances in the treatment of chronic lymphocytic leukemia (CLL), ASCO named the approval of four new drugs for this disease in 2014 as its first “Advance of the Year.”